The Travel Vaccines Market Worth $2,224m by 2019: New Forecast Report

2013-05-21
Published : May-2013

GBI Research estimated the travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012. The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.
This new report “Travel Vaccines Market to 2019 Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth” provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market. The report analyzes the market for Travel Vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. In addition, it provides overview of vaccines market in India, China and Australia including regulatory frameworks and profiles of the top companies, deals and pipeline analysis. The report discusses the global pipeline for Travel Vaccines across various stages of development.

 

                                                             Request Sample

 

A Strong Pipeline in which Nearly 30% of Vaccine Candidates are in Phase III and Phase II

The global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed.

Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines’ ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.

Hepatitis A Vaccines, Japanese Encephalitis Vaccines and Meningococcal Vaccines Account for More than Half of the Market

Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each.

Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15–20 years, rather than being lifelong, which is expected to drive future growth.

Major Companies Profiled in this report (http://www.reportsnreports.com/reports/247361-travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth.html) include:

  • GlaxoSmithKline
  • Sanofi
  • Pfizer
  • Merck
  • Novartis

List Of Tables

Table 1: Travel Vaccines Market, Top Seven Markets, Vaccine-Preventable Diseases, 2012 15
Table 2: Travel Vaccines Market, Top Seven Markets, Traveler Population (million), 2007–2012 24
Table 3: Travel Vaccines Market, Top Seven Markets, Traveler Population Forecast (million), 2012–2019 25
Table 4: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue ($m), 2007–2012 28
Table 5: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue Forecast ($m), 2012–2019 28
Table 6: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue ($m), 2007–2012 29
Table 7: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue Forecast ($m), 2012–2019 29
Table 8: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue ($m), 2007–2012 30
Table 9: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue Forecast ($m), 2012–2019 30
Table 10: Travel Vaccines Market, US, Hepatitis A Vaccines, Cost ($), 2007–2012 31
Table 11: Travel Vaccines Market, US, Hepatitis A Vaccines, Cost ($), 2012–2019 31
Table 12: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Cost ($), 2007–2012 31
Table 13: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Cost Forecast ($), 2012–2019 31
Table 14: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Cost ($), 2007–2012 32
Table 15: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Cost Forecast ($), 2012–2019 32
Table 16: Travel Vaccines Market, Global, Hepatitis A Vaccines, Phase III (Inactive) Pipeline, 2012 33
Table 17: Travel Vaccines Market, Global, Hepatitis A Vaccines, Preclinical and Discovery (Inactive) Pipeline, 2012 33
Table 18: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue ($m), 2007–2012 35
Table 19: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue Forecast ($m), 2012–2019 35
Table 20: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue ($m), 2007–2012 36
Table 21: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue Forecast ($m), 2012–2019 36
Table 22: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue ($m), 2007–2012 37
Table 23: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue Forecast ($m), 2012–2019 37
Table 24: Travel Vaccines Market, US, Hepatitis B Vaccines, Cost ($), 2007–2012 38
Table 25: Travel Vaccines Market, US, Hepatitis B Vaccines, Cost Forecast ($), 2012–2019 38
Table 26: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Cost ($), 2007–2012 38
Table 27: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Cost ($), 2012–2019 38
Table 28: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Cost ($), 2007–2012 39
Table 29: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Cost Forecast ($), 2012–2019 39
Table 30: Travel Vaccines Market, Global, Hepatitis B Vaccines, Registration and Phase III Pipeline, 2012 40
Table 31: Travel Vaccines Market, Global, Hepatitis B Vaccines, Phase II Pipeline, 2012 40
Table 32: Travel Vaccines Market, Global, Hepatitis B Vaccines, Phase I Pipeline, 2012 40
Table 33: Travel Vaccines Market, Global, Hepatitis B Vaccines, Preclinical and Discovery Pipeline, 2012 41
Table 34: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue ($m), 2007–2012 43
Table 35: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2012–2019 43
Table 36: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Revenue ($m), 2007–2012 44
Table 37: Travel Vaccines Market to 2019, Japanese Encephalitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2012–2019 44
Table 38: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue ($m), 2007–2012 45
Table 39: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2012–2019 45
Table 40: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Cost ($), 2007–2012 46
Table 41: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012–2019 46
Table 42: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Cost ($), 2007–2012 46
Table 43: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012–2019 46
Table 44: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Cost ($), 2007–2012 47
Table 45: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Cost Forecast ($), 2012–2019 47
Table 46: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Registration, 2012 48
Table 47: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Preclinical and Discovery, 2012 48
Table 48: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue ($m), 2007–2012 50
Table 49: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue Forecast ($m), 2012–2019 50
Table 50: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue ($m), 2007–2012 51
Table 51: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue Forecast ($m), 2012–2019 51
Table 52: Travel Vaccines Market, US, Meningococcal Vaccines, Cost ($), 2007–2012 52
Table 53: Travel Vaccines Market, US, Meningococcal Vaccines, Cost Forecast ($), 2012–2019 52
Table 54: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Cost ($), 2007–2012 52
Table 55: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Cost Forecast ($), 2012–2019 52
Table 56: Travel Vaccines Market, Global, Meningococcal Vaccines, Registration and Phase III Pipeline, 2012 53
Table 57: Travel Vaccines Market, Global, Meningococcal Vaccines, Phase II Pipeline, 2012 54
Table 58: Travel Vaccines Market, Global, Meningococcal Vaccines, Preclinical Pipeline, 2012 54
Table 59: Travel Vaccines Market, US, Rabies Vaccines, Revenue ($m), 2007–2012 56
Table 60: Travel Vaccines Market, US, Rabies Vaccines, Revenue Forecast ($m), 2012–2019 56
Table 61: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue ($m), 2007–2012 57
Table 62: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue Forecast ($m), 2012–2019 57
Table 63: Travel Vaccines Market, Japan, Rabies Vaccines, Revenue ($m), 2007–2012 58
Table 64: Travel Vaccines Market, Japan, Rabies Vaccines, Revenue Forecast ($m), 2012–2019 58
Table 65: Travel Vaccines Market, US, Rabies Vaccines, Cost ($), 2007–2012 59
Table 66: Travel Vaccines Market, US, Rabies Vaccines, Cost Forecast ($), 2012–2019 59
Table 67: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Cost ($), 2007–2012 59
Table 68: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Cost Forecast ($), 2012–2019 59
Table 69: Travel Vaccines Market, Japan, Rabies Vaccines, Cost ($), 2007–2012 60
Table 70: Travel Vaccines Market, Japan. Rabies Vaccines, Cost Forecast ($), 2012–2019 60
Table 71: Travel Vaccines Market, Global, Rabies Vaccines, Phase II Pipeline, 2012 61
Table 72: Travel Vaccines Market, Global, Rabies Vaccines, Phase I Pipeline, 2012 61
Table 73: Travel Vaccines Market, Global, Rabies Vaccines, Preclinical Pipeline, 2012 61
Table 74: Travel Vaccines Market, US, Typhoid Vaccines, Revenue ($m), 2007–2012 63
Table 75: Travel Vaccines Market, US, Typhoid Vaccines, Revenue Forecast ($m), 2012–2019 63
Table 76: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue ($m), 2007–2012 64
Table 77: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue Forecast ($m), 2012–2019 64
Table 78: Travel Vaccines Market, US, Typhoid Vaccines, Cost ($), 2007–2012 65
Table 79: Travel Vaccines Market, US, Typhoid Vaccines, Cost Forecast ($), 2012–2019 65
Table 80: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Cost ($), 2007–2012 65
Table 81: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Cost Forecast ($), 2012–2019 65
Table 82: Travel Vaccines Market, Global, Typhoid Vaccines, Phase II Pipeline, 2012 66
Table 83: Travel Vaccines Market, Global, Typhoid Vaccines, Preclinical Pipeline, 2012 66
Table 84: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue ($m), 2007–2012 68
Table 85: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue Forecast ($m), 2012–2019 68
Table 86: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue ($m), 2007–2012 69
Table 87: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue Forecast ($m), 2012–2019 69
Table 88: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue ($m), 2007–2012 70
Table 89: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue Forecast ($m), 2012–2019 70
Table 90: Travel Vaccines Market, US, Yellow Fever Vaccines, Cost ($), 2007–2012 71
Table 91: Travel Vaccines Market, US, Yellow Fever Vaccines, Cost Forecast ($), 2012–2019 71
Table 92: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Cost ($), 2007–2012 71
Table 93: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Cost Forecast ($), 2012–2019 71
Table 94: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Cost ($), 2007–2012 72
Table 95: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Cost Forecast ($), 2012–2019 72
Table 96: Travel Vaccines Market, Global, Yellow Fever Vaccines, Phase III, 2012 73
Table 97: Travel Vaccines Market, Global, Yellow Fever Vaccines, Phase I, 2012 73
Table 98: Travel Vaccines Market, Global, Yellow Fever Vaccines, Preclinical and Discovery, 2012 73
Table 99: Travel Vaccines Market, India, Immunization Schedule, 2012 87
Table 100: Travel Vaccines Market, India, Major Vaccine Brands by Indication, 2012 88
Table 101: Travel Vaccines Market, China, Policies, 2012 95
Table 102: Travel Vaccines Market, Australia, Designated Bacterial Vaccines and Circumstances in which Vaccines may be Provided, 2011 98
Table 103: Travel Vaccines Market, Australia, Designated Viral Vaccines and Circumstances in which Vaccines may be Provided, 2011 100
Table 104: Travel Vaccines Market, Australia, Designated Combined Bacterial and Viral Vaccines and Circumstances in which Vaccines may be Provided, 2011 103
Table 105: Travel Vaccines Market, Australia, Immunization Schedule, 2012 104
Table 106: Travel Vaccines Market, Emerging Markets, Pipeline by Phase, 2012 110

List Of Figures

Figure 1: Travel Vaccines Market, Global, Vaccine Types, 2012 16
Figure 2: Travel Vaccines Market, Global, Vaccine Manufacturing Process, 2012 20
Figure 3: Travel Vaccines Market, Top Seven Markets, Revenue Forecast ($m), 2007–2019 21
Figure 4: Travel Vaccines Market, Top Seven Markets, Market Share by Vaccine Type (%), 2012 22
Figure 5: Travel Vaccines Market, Top Seven Markets, Market Share by Geography (%), 2012 23
Figure 6: Travel Vaccines Market, Top Seven Markets, Traveling Population (million), 2007–2019 24
Figure 7: Travel Vaccines Market, Global, Geographical Distribution of Hepatitis A, 2012 27
Figure 8: Travel Vaccines Market, US, Hepatitis A Vaccines, Revenue Forecast ($m), 2007–2019 28
Figure 9: Travel Vaccines Market, Top Five European Countries, Hepatitis A Vaccines, Revenue Forecast ($m), 2007–2019 29
Figure 10: Travel Vaccines Market, Japan, Hepatitis A Vaccines, Revenue Forecast ($m), 2007–2019 30
Figure 11: Travel Vaccines Market, Global, Hepatitis A Vaccines, Pipeline by Phase (%), 2012 32
Figure 12: Travel Vaccines Market, Global, Geographical Distribution of Hepatitis B, 2012 34
Figure 13: Travel Vaccines Market, US, Hepatitis B Vaccines, Revenue Forecast ($m), 2007–2019 35
Figure 14: Travel Vaccines Market, Top Five European Countries, Hepatitis B Vaccines, Revenue Forecast ($m), 2007–2019 36
Figure 15: Travel Vaccines Market, Japan, Hepatitis B Vaccines, Revenue Forecast ($m), 2007–2019 37
Figure 16: Travel Vaccines Market, Global, Hepatitis B Vaccines, Pipeline by Phase (%), 2012 39
Figure 17: Travel Vaccines Market, Global, Geographical Distribution of Japanese Encephalitis, 2012 42
Figure 18: Travel Vaccines Market, US, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007–2019 43
Figure 19: Travel Vaccines Market, Top Five European Countries, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007–2019 44
Figure 20: Travel Vaccines Market, Japan, Japanese Encephalitis Vaccines, Revenue Forecast ($m), 2007–2019 45
Figure 21: Travel Vaccines Market, Global, Japanese Encephalitis Vaccines, Pipeline by Phase (%), 2012 47
Figure 22: Travel Vaccines Market, Global, Geographical Distribution of Meningococcal Meningitis, 2012 49
Figure 23: Travel Vaccines Market, US, Meningococcal Vaccines, Revenue Forecast ($m), 2007–2019 50
Figure 24: Travel Vaccines Market, Top Five European Countries, Meningococcal Vaccines, Revenue Forecast ($m), 2007–2019 51
Figure 25: Travel Vaccines Market, Global, Meningococcal Vaccines, Pipeline by Phase (%), 2012 53
Figure 26: Travel Vaccines Market, Global, Geographical Distribution of Rabies, 2012 55
Figure 27: Travel Vaccines Market, US, Rabies Vaccines, Revenue Forecast ($m), 2007–2019 56
Figure 28: Travel Vaccines Market, Top Five European Countries, Rabies Vaccines, Revenue Forecast ($m), 2007–2019 57
Figure 29: Travel Vaccines Market, Japan. Rabies Vaccines, Revenue Forecast ($m), 2007–2019 58
Figure 30: Travel Vaccines Market, Global, Rabies Vaccines, Pipeline by Phase (%), 2012 60
Figure 31: Travel Vaccines Market, Global, Geographical Distribution of Typhoid, 2012 62
Figure 32: Travel Vaccines Market, US, Typhoid Vaccines, Revenue Forecast ($m), 2007–2019 63
Figure 33: Travel Vaccines Market, Top Five European Countries, Typhoid Vaccines, Revenue Forecast ($m), 2007–2019 64
Figure 34: Travel Vaccines Market, Global, Typhoid Vaccines, Pipeline by Phase (%), 2012 66
Figure 35: Travel Vaccines Market, Global, Geographical Distribution of Yellow Fever, 2012 67
Figure 36: Travel Vaccines Market, US, Yellow Fever Vaccines, Revenue Forecast ($m), 2007–2019 68
Figure 37: Travel Vaccines Market, Top Five European Countries, Yellow Fever Vaccines, Revenue Forecast ($m), 2007–2019 69
Figure 38: Travel Vaccines Market, Japan, Yellow Fever Vaccines, Revenue Forecast ($m), 2007–2019 70
Figure 39: Travel Vaccines Market, Global, Yellow Fever Vaccines, Pipeline by Phase (%), 2012 72
Figure 40: GlaxoSmithKline, Travel Vaccines Market, SWOT Analysis, 2012 75
Figure 41: Sanofi, Travel Vaccines Market, SWOT Analysis, 2012 76
Figure 42: Pfizer, Travel Vaccines Market, SWOT Analysis, 2012 77
Figure 43: Merck, Travel Vaccines Market, SWOT Analysis, 2012 78
Figure 44: Novartis, Travel Vaccines Market, SWOT Analysis, 2012 79
Figure 45: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Year, 2009–2013 80
Figure 46: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Type, 2008–2013 81
Figure 47: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Value, 2008–2013 82
Figure 48: Travel Vaccines Market, Global, Strategic Consolidations, Deals by Geography, 2008–2013 83
Figure 49: Vaccines in Emerging Markets, India, National Rural Health Mission, 2011 86
Figure 50: Vaccines in Emerging Markets, Deals by Year, 2009–2013 107
Figure 51: Travel Vaccines Market, Emerging Markets, Deals by Type (%), 2009–2013 108
Figure 52: Travel Vaccines Market, Emerging Markets, Deals by Value ($m), 2009–2013 109
Figure 53: Travel Vaccines Market, Emerging Markets, Pipeline by Phase (%), 2012 110
Figure 54: GBI Research Market Forecasting Model 115

Contact [email protected] for further information.

 

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

“The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......
 $

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

“Digital Pharmacy market to register a CAGR of 17.0%  during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated  to grow at the highest rate during the forecast period” On the basis  ofdrug type, t......
 $4950

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

“Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......
 $4950

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......
 $4950

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

“Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy